HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy

• Published in: Modern pathology Vol. 33; no. 1; pp. 118 - 127
• Main Authors: Rottmann, Douglas, Snir, Olivia L., Wu, Xinyu, Wong, Serena, Hui, Pei, Santin, Alessandro D., Buza, Natalia
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 2020; Elsevier Limited
• Subjects: 13; 13/51; 38; 38/32; 45; 631/67/1517/1931; 692/53/2423; Aged; Aged, 80 and over; Biomarkers, Tumor - analysis; Breast; Carboplatin; Carcinoma; Carcinosarcoma - genetics; Carcinosarcoma - metabolism; Carcinosarcoma - pathology; Chemotherapy; Endometrium; ErbB-2 protein; Fallopian Tube Neoplasms - genetics; Fallopian Tube Neoplasms - metabolism; Fallopian Tube Neoplasms - pathology; Female; Gene Amplification; Genital tract; Humans; Immunohistochemistry; Laboratory Medicine; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Molecular Targeted Therapy; Monoclonal antibodies; Paclitaxel; Pathology; Receptor, ErbB-2 - analysis; Receptor, ErbB-2 - genetics; Receptor, ErbB-2 - metabolism; Sarcoma; Trastuzumab; Tumors; Uterine Neoplasms - genetics; Uterine Neoplasms - metabolism; Uterine Neoplasms - pathology; Uterus

A recent phase II clinical trial showed increased progression-free survival in patients with HER2-positive endometrial serous carcinoma receiving trastuzumab in addition to carboplatin–paclitaxel chemotherapy. Similar to endometrial serous carcinomas, carcinosarcomas of the female genital tract have...